A. D. Dios

发表

p38 mitogen‐activated protein kinase inhibitor LY2228820 enhances bortezomib‐induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications

K. Anderson, N. Munshi, R. Campbell, 2008, British journal of haematology.

Small Molecule Therapeutics A Novel CDK 9 Inhibitor Shows Potent Antitumor Ef fi cacy in Preclinical Hematologic Tumor Models

R. Gaynor, Y. Qian, Jian Du, 2014 .

Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts.

Thomas J. Raub, L. Gelbert, Concha Sánchez-Martínez, 2011 .

Highly diastereoselective bis-hydroxylation of a protected conduritol B: a short route to myo-inositol derivatives.

O. Arjona, R. F. D. L. Pradilla, A. D. Dios, 1991 .

CDK 6 Inhibitors and the Antitumor Activity of CDK 4 and 6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

Thomas J. Raub, L. Gelbert, Concha Sánchez-Martínez, 2015 .

Synthesis and Diastereoselective Complexation of Enantiopure Sulfinyl Dienes: The Preparation of Sulfinyl Iron(0) Dienes

D. Mcculley, L. Estroff, R. F. D. L. Pradilla, 1997 .

Acyl sulfonamide anti-proliferatives. Part 2: activity of heterocyclic sulfonamide derivatives.

Sean R. Dinn, P. Hipskind, C. Shih, 2005, Bioorganic & medicinal chemistry letters.

Diastereoselective synthesis of 4-substituted 5-(p-tolylsulfinyl)-5,6-dehydropiperidin-2-ones. A new approach to methyl L-(2S, 4S)-4-methyl-6-oxopipecolate

C. Alvarez-Ibarra, M. Quiroga, A. D. Dios, 2001 .

Sulfoxide-mediated diastereoselective Michael additions. New enantioselective synthesis of C-4 substituted 2-pyroaminoadipic acids

C. Alvarez-Ibarra, A. D. Dios, H. Acherki, 1999 .

Polar vs steric effects in the 1,3-dipolar cycloaddition reactions of acetonitrile oxide and 2-endO-acetoxy-5-halo-7-oxabicyclo[2.2.1]hept-5-en-2-exo-carbonitrile

O. Arjona, J. Plumet, R. F. D. L. Pradilla, 1990 .

Regio- and stereocontrolled alkylative ring opening of unsymmetrical 8-oxabicyclo[3.2.1]octene systems. Synthesis of highly substituted hydroxycycloheptenyl sulfones.

O. Arjona, J. Plumet, A. D. Dios, 1993 .

Highly diastereoselective bis-hydroxylation of the amino-deoxy-conduritol C ring system. A formal synthesis of the aminocyclitol moiety of the antibiotic Hygromycin A

B. Sáez, O. Arjona, J. Plumet, 1995 .

Sulfone directed alkylative bridge cleavage of oxabicyclic vinyl sulfones with organolithium reagents

A. Viso, O. Arjona, J. Plumet, 1994 .

Synthesis of optically pure, differentially protected 1,4- and 1,6-mannosyl-D-myo-inositol derivatives from 7-oxabicyclo[2.2.1]heptan-2-one

O. Arjona, A. D. Dios, C. Montero, 1995 .

Abstract 3101: In-vitro characterization of Abemaciclib pharmacology in ER+ breast cancer cell lines

Jian Du, R. Beckmann, S. Buchanan, 2015 .

Small Molecule Therapeutics Characterization of LY 2228820 Dimesylate , a Potent and Selective Inhibitor of p 38 MAPK with Antitumor Activity

R. Campbell, J. Velasco, J. Graff, 2014 .

Characterization of LY 2228820 dimesylate , a potent and selective inhibitor of p 38 MAPK with anti-tumor activity

R. Campbell, J. Velasco, J. Graff, 2013 .

Osmium-Mediated Asymmetric Synthesis of Glycosyl-myo-inositols from Oxanorbornanes.

O. Arjona, J. Plumet, R. F. D. L. Pradilla, 1992 .

Abstract B233: Identification and characterization of LY2835219: A potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity.

L. Gelbert, Concha Sánchez-Martínez, B. Neubauer, 2011 .

Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)

Brian E. Mattioni, C. Mur, T. K. Baker, 2021, Experimental and Molecular Therapeutics.

Structural and conformational studies of 5-(1H-pyrrol-2-ylmethylene)-substituted imidazolidine-2,4-diones and thiazolidine-2,4-diones

J. Espinosa, A. D. Dios, M. L. D. L. Puente, 2002 .

A novel CDK9 inhibitor shows potent anti-tumor efficacy in preclinical hematological tumor models

R. Gaynor, X. Ye, J. J. Starling, 2014 .